score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat60		
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S1561L	0.2194	155.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0				ALK p.S1561L (Missense)		MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	MEL-IPI_Pat60-Normal-SM-4NFVR
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.Q79K	0.2239	67.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230													0				AKT1 p.Q79K (Missense)	0.0	MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	MEL-IPI_Pat60-Normal-SM-4NFVR
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Deletion	p.600_601VK>E	0.4396	298.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.600_601VK>E (Deletion)	1.0	MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	MEL-IPI_Pat60-Normal-SM-4NFVR
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Deletion	p.600_601VK>E	0.3797	345.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.600_601VK>E (Deletion)	1.0	MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	MEL-IPI_Pat60-Normal-SM-4NFVR
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Nonsense	p.W1043*	0.2532	154.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0				CDK12 p.W1043* (Nonsense)	0.0	MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	MEL-IPI_Pat60-Normal-SM-4NFVR
Investigate Actionability	Guideline			Somatic Variant	TET2	Nonsense	p.Q652*	0.3158	57.0	8e-06	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf													0				TET2 p.Q652* (Nonsense)		MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	MEL-IPI_Pat60-Normal-SM-4NFVR
Investigate Actionability	Preclinical			Copy Number	FGFR2	Deletion				0.0	0.0		Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR2 Deletion		MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Splice Site	p.R412R	0.2174	23.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823						0				ESR1 p.R412R (Splice Site)		MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	MEL-IPI_Pat60-Normal-SM-4NFVR
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.M951I	0.2807	431.0	0.0	0.0																Investigate Actionability	0.0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060	0				BLM p.M951I (Missense)		MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	MEL-IPI_Pat60-Normal-SM-4NFVR
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D735N	0.2846	123.0	0.0	0.0																					0				ROS1 p.D735N (Missense)		MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	MEL-IPI_Pat60-Normal-SM-4NFVR
Biologically Relevant				Copy Number	PMS2	Amplification				0.0	0.0																					0				PMS2 Amplification		MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	
Biologically Relevant				Copy Number	EWSR1	Deletion				0.0	0.0																					0				EWSR1 Deletion		MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	
Biologically Relevant				Copy Number	CHEK2	Deletion				0.0	0.0																					0				CHEK2 Deletion		MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	
Biologically Relevant				Copy Number	LIMK2	Deletion				0.0	0.0																					0				LIMK2 Deletion		MEL-IPI_Pat60	MEL-IPI_Pat60-Tumor-SM-4DK2L	
Biologically Relevant				Microsatellite Stability	Supporting variants		PMS2 Amplification, PRDM2 Deletion, PRDM2 p.E1261del (Deletion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PMS2 Amplification, PRDM2 Deletion, PRDM2 p.E1261del (Deletion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat60		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.827																									0				COSMIC Signature (version 2) 7 (83%)		MEL-IPI_Pat60		
